Amy Desrochers Divasta, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometriosis | 23 | 2024 | 874 | 5.160 |
Why?
|
| Anorexia Nervosa | 23 | 2024 | 1364 | 4.920 |
Why?
|
| Polycystic Ovary Syndrome | 7 | 2020 | 383 | 2.010 |
Why?
|
| Bone Density | 15 | 2024 | 3574 | 2.000 |
Why?
|
| Contraceptive Agents, Female | 4 | 2024 | 123 | 1.910 |
Why?
|
| Norethindrone | 4 | 2018 | 56 | 1.900 |
Why?
|
| Gonadotropin-Releasing Hormone | 6 | 2023 | 1149 | 1.680 |
Why?
|
| Levonorgestrel | 4 | 2024 | 80 | 1.670 |
Why?
|
| Dehydroepiandrosterone | 5 | 2019 | 259 | 1.500 |
Why?
|
| Intrauterine Devices | 2 | 2023 | 115 | 1.380 |
Why?
|
| Gynecomastia | 6 | 2022 | 88 | 1.360 |
Why?
|
| Leuprolide | 3 | 2018 | 313 | 1.240 |
Why?
|
| Estrogens, Conjugated (USP) | 4 | 2018 | 277 | 1.130 |
Why?
|
| Amenorrhea | 6 | 2022 | 484 | 1.070 |
Why?
|
| Adolescent | 81 | 2024 | 89244 | 1.070 |
Why?
|
| Pelvic Pain | 7 | 2024 | 300 | 1.000 |
Why?
|
| Malnutrition | 4 | 2014 | 632 | 1.000 |
Why?
|
| Ovarian Diseases | 2 | 2020 | 137 | 0.980 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2024 | 30 | 0.920 |
Why?
|
| Contraceptives, Oral, Combined | 4 | 2023 | 118 | 0.900 |
Why?
|
| Dyspareunia | 2 | 2022 | 48 | 0.880 |
Why?
|
| Intrauterine Devices, Copper | 1 | 2023 | 30 | 0.870 |
Why?
|
| Ethinyl Estradiol | 4 | 2019 | 114 | 0.860 |
Why?
|
| Young Adult | 51 | 2024 | 60131 | 0.810 |
Why?
|
| Absorptiometry, Photon | 12 | 2019 | 1758 | 0.800 |
Why?
|
| Adolescent Medicine | 1 | 2021 | 73 | 0.750 |
Why?
|
| Bone and Bones | 5 | 2013 | 2590 | 0.710 |
Why?
|
| Estrogens | 7 | 2022 | 1536 | 0.700 |
Why?
|
| Menstruation Disturbances | 2 | 2023 | 143 | 0.690 |
Why?
|
| Progestins | 3 | 2023 | 302 | 0.690 |
Why?
|
| Hormone Replacement Therapy | 5 | 2018 | 757 | 0.680 |
Why?
|
| Hypertrophy | 8 | 2022 | 562 | 0.680 |
Why?
|
| Dysmenorrhea | 3 | 2022 | 107 | 0.680 |
Why?
|
| Anti-Mullerian Hormone | 2 | 2024 | 420 | 0.640 |
Why?
|
| Contraception | 5 | 2023 | 362 | 0.640 |
Why?
|
| Ovarian Follicle | 1 | 2020 | 244 | 0.630 |
Why?
|
| Breast | 12 | 2022 | 1976 | 0.590 |
Why?
|
| Mammaplasty | 8 | 2022 | 1263 | 0.550 |
Why?
|
| Tibia | 3 | 2019 | 1076 | 0.550 |
Why?
|
| Quality of Life | 14 | 2022 | 13510 | 0.520 |
Why?
|
| Telemedicine | 2 | 2024 | 3110 | 0.500 |
Why?
|
| Female | 82 | 2024 | 397515 | 0.500 |
Why?
|
| Osteoporosis | 3 | 2016 | 1606 | 0.470 |
Why?
|
| Vibration | 1 | 2016 | 335 | 0.470 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2020 | 454 | 0.460 |
Why?
|
| Bed Rest | 2 | 2016 | 83 | 0.450 |
Why?
|
| Longitudinal Studies | 12 | 2024 | 14794 | 0.420 |
Why?
|
| Bone Remodeling | 1 | 2016 | 583 | 0.420 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 365 | 0.410 |
Why?
|
| Wernicke Encephalopathy | 1 | 2012 | 29 | 0.400 |
Why?
|
| Humans | 93 | 2024 | 768970 | 0.380 |
Why?
|
| Uterine Hemorrhage | 3 | 2023 | 237 | 0.380 |
Why?
|
| Double-Blind Method | 9 | 2024 | 12467 | 0.370 |
Why?
|
| Glucose Tolerance Test | 1 | 2014 | 1183 | 0.360 |
Why?
|
| Ergocalciferols | 1 | 2011 | 110 | 0.350 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 1281 | 0.340 |
Why?
|
| Ovary | 1 | 2014 | 965 | 0.340 |
Why?
|
| Glucose Intolerance | 1 | 2014 | 579 | 0.330 |
Why?
|
| Overweight | 4 | 2022 | 2448 | 0.330 |
Why?
|
| Exercise | 4 | 2016 | 5954 | 0.320 |
Why?
|
| Homosexuality, Female | 2 | 2020 | 171 | 0.300 |
Why?
|
| Prediabetic State | 1 | 2014 | 548 | 0.300 |
Why?
|
| Menstruation | 2 | 2023 | 310 | 0.290 |
Why?
|
| Contraceptive Agents | 3 | 2023 | 148 | 0.280 |
Why?
|
| Acne Vulgaris | 2 | 2024 | 352 | 0.270 |
Why?
|
| Self Concept | 4 | 2017 | 1046 | 0.270 |
Why?
|
| Spinal Fractures | 1 | 2013 | 712 | 0.260 |
Why?
|
| Lumbar Vertebrae | 2 | 2013 | 1889 | 0.250 |
Why?
|
| Adult | 33 | 2024 | 223851 | 0.250 |
Why?
|
| Ultrasonography | 4 | 2020 | 6002 | 0.250 |
Why?
|
| Artifacts | 1 | 2014 | 1942 | 0.250 |
Why?
|
| Migraine Disorders | 1 | 2018 | 1713 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3235 | 0.250 |
Why?
|
| Femur | 2 | 2014 | 1321 | 0.240 |
Why?
|
| Musculoskeletal System | 1 | 2007 | 188 | 0.240 |
Why?
|
| Weight Loss | 2 | 2015 | 2721 | 0.230 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 2913 | 0.230 |
Why?
|
| Child | 23 | 2024 | 80960 | 0.230 |
Why?
|
| Hip | 3 | 2014 | 256 | 0.230 |
Why?
|
| Hypogonadism | 1 | 2010 | 805 | 0.230 |
Why?
|
| Boston | 5 | 2018 | 9377 | 0.230 |
Why?
|
| Heterosexuality | 3 | 2021 | 309 | 0.220 |
Why?
|
| Case-Control Studies | 9 | 2022 | 22296 | 0.220 |
Why?
|
| Mass Screening | 2 | 2016 | 5457 | 0.210 |
Why?
|
| Insulin Resistance | 3 | 2014 | 3982 | 0.200 |
Why?
|
| Medroxyprogesterone | 1 | 2021 | 35 | 0.200 |
Why?
|
| Hunger | 1 | 2023 | 207 | 0.190 |
Why?
|
| Age Factors | 5 | 2021 | 18435 | 0.190 |
Why?
|
| Carbohydrates | 1 | 2023 | 389 | 0.190 |
Why?
|
| Body Mass Index | 11 | 2018 | 13055 | 0.190 |
Why?
|
| Syncope | 1 | 2004 | 430 | 0.190 |
Why?
|
| Cholecalciferol | 2 | 2020 | 557 | 0.190 |
Why?
|
| Peritoneal Diseases | 1 | 2021 | 76 | 0.190 |
Why?
|
| Quality Improvement | 1 | 2016 | 3860 | 0.180 |
Why?
|
| Obesity | 6 | 2022 | 13091 | 0.180 |
Why?
|
| Hyperinsulinism | 2 | 2014 | 402 | 0.180 |
Why?
|
| Primary Health Care | 2 | 2016 | 4748 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 6320 | 0.170 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2022 | 183 | 0.170 |
Why?
|
| Body Image | 2 | 2015 | 646 | 0.170 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 26395 | 0.170 |
Why?
|
| Comorbidity | 5 | 2024 | 10592 | 0.160 |
Why?
|
| Device Removal | 1 | 2024 | 643 | 0.160 |
Why?
|
| Mastocytosis, Systemic | 1 | 2021 | 102 | 0.160 |
Why?
|
| Heart | 2 | 2010 | 4447 | 0.160 |
Why?
|
| Pain Threshold | 1 | 2023 | 606 | 0.160 |
Why?
|
| Femur Neck | 2 | 2014 | 318 | 0.160 |
Why?
|
| Pregnancy in Adolescence | 1 | 2020 | 166 | 0.150 |
Why?
|
| Research Subjects | 1 | 2020 | 249 | 0.150 |
Why?
|
| Menarche | 1 | 2021 | 538 | 0.150 |
Why?
|
| Pregnancy, Unplanned | 1 | 2019 | 86 | 0.150 |
Why?
|
| Body Composition | 4 | 2014 | 2462 | 0.150 |
Why?
|
| Menstrual Cycle | 1 | 2021 | 546 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 36854 | 0.150 |
Why?
|
| Infertility, Female | 1 | 2024 | 764 | 0.150 |
Why?
|
| Adiponectin | 1 | 2023 | 1117 | 0.150 |
Why?
|
| Vascular Malformations | 2 | 2014 | 469 | 0.140 |
Why?
|
| Retrospective Studies | 9 | 2024 | 81903 | 0.140 |
Why?
|
| Contraception Behavior | 1 | 2019 | 187 | 0.140 |
Why?
|
| Hospitalization | 3 | 2016 | 10847 | 0.140 |
Why?
|
| United States | 7 | 2024 | 73186 | 0.140 |
Why?
|
| Delayed Diagnosis | 2 | 2018 | 468 | 0.140 |
Why?
|
| Eating | 1 | 2023 | 1542 | 0.140 |
Why?
|
| Neuralgia | 1 | 2023 | 622 | 0.130 |
Why?
|
| Anxiety | 2 | 2023 | 4672 | 0.130 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2016 | 16 | 0.130 |
Why?
|
| Aftercare | 1 | 2022 | 921 | 0.130 |
Why?
|
| Hydrocortisone | 1 | 2023 | 1841 | 0.120 |
Why?
|
| Administration, Oral | 3 | 2018 | 4040 | 0.120 |
Why?
|
| Leptin | 1 | 2023 | 1597 | 0.120 |
Why?
|
| Knee | 1 | 2017 | 278 | 0.120 |
Why?
|
| Physical Stimulation | 1 | 2016 | 517 | 0.120 |
Why?
|
| Nausea | 1 | 2017 | 682 | 0.120 |
Why?
|
| Receptors, FSH | 1 | 2014 | 29 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2020 | 828 | 0.110 |
Why?
|
| Nurses | 1 | 2024 | 2501 | 0.110 |
Why?
|
| Sexual Behavior | 3 | 2021 | 2200 | 0.110 |
Why?
|
| Prospective Studies | 11 | 2024 | 54962 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 13021 | 0.110 |
Why?
|
| Adipose Tissue | 2 | 2017 | 3335 | 0.110 |
Why?
|
| Fertility Agents, Female | 1 | 2013 | 101 | 0.110 |
Why?
|
| Pandemics | 2 | 2023 | 8749 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 14752 | 0.100 |
Why?
|
| Vascular Neoplasms | 1 | 2014 | 167 | 0.100 |
Why?
|
| Hyperandrogenism | 1 | 2012 | 46 | 0.100 |
Why?
|
| Sexual Maturation | 1 | 2014 | 258 | 0.100 |
Why?
|
| Receptors, Somatotropin | 1 | 2012 | 58 | 0.100 |
Why?
|
| Age Distribution | 1 | 2018 | 2875 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2020 | 65480 | 0.100 |
Why?
|
| Bone Resorption | 1 | 2015 | 728 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 8055 | 0.090 |
Why?
|
| Risk Factors | 8 | 2024 | 74976 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2024 | 41808 | 0.090 |
Why?
|
| Spine | 2 | 2009 | 1141 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 1399 | 0.090 |
Why?
|
| Lymphatic Abnormalities | 1 | 2012 | 134 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2024 | 15951 | 0.090 |
Why?
|
| Mental Health | 2 | 2015 | 3275 | 0.090 |
Why?
|
| Risk-Taking | 1 | 2016 | 1023 | 0.090 |
Why?
|
| Calcifediol | 1 | 2011 | 160 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 12253 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 3492 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2018 | 24333 | 0.090 |
Why?
|
| Age of Onset | 1 | 2017 | 3346 | 0.090 |
Why?
|
| Calcification, Physiologic | 1 | 2010 | 171 | 0.080 |
Why?
|
| Heart Function Tests | 1 | 2010 | 317 | 0.080 |
Why?
|
| Medical History Taking | 1 | 2013 | 779 | 0.080 |
Why?
|
| Postoperative Period | 3 | 2020 | 1830 | 0.080 |
Why?
|
| Pain | 3 | 2023 | 5100 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 39394 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 15661 | 0.080 |
Why?
|
| Contraceptives, Oral | 2 | 2012 | 561 | 0.080 |
Why?
|
| Osteocalcin | 1 | 2009 | 277 | 0.080 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 716 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2013 | 1194 | 0.080 |
Why?
|
| Observer Variation | 1 | 2014 | 2623 | 0.080 |
Why?
|
| Immobilization | 1 | 2009 | 229 | 0.070 |
Why?
|
| Reference Values | 2 | 2023 | 4940 | 0.070 |
Why?
|
| Metformin | 2 | 2012 | 909 | 0.070 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2008 | 144 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 999 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2020 | 9684 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4862 | 0.070 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1159 | 0.070 |
Why?
|
| Body Weight | 2 | 2014 | 4628 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2017 | 3782 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2017 | 2936 | 0.070 |
Why?
|
| Prevalence | 3 | 2024 | 15879 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2012 | 1110 | 0.070 |
Why?
|
| Massachusetts | 1 | 2019 | 8894 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2006 | 156 | 0.060 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 864 | 0.060 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 1091 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 3780 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 606 | 0.060 |
Why?
|
| Weight Gain | 2 | 2020 | 2359 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 1672 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 1803 | 0.060 |
Why?
|
| Infant | 3 | 2023 | 36556 | 0.060 |
Why?
|
| Syncope, Vasovagal | 1 | 2004 | 39 | 0.060 |
Why?
|
| Weight-Bearing | 1 | 2007 | 534 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2252 | 0.060 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 1388 | 0.060 |
Why?
|
| Depression | 1 | 2023 | 8231 | 0.060 |
Why?
|
| Nutritional Status | 2 | 2009 | 1627 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10765 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2013 | 2649 | 0.050 |
Why?
|
| Hypoglycemic Agents | 2 | 2012 | 3110 | 0.050 |
Why?
|
| Vitamins | 1 | 2011 | 1638 | 0.050 |
Why?
|
| Phenotype | 1 | 2020 | 16731 | 0.050 |
Why?
|
| Anthropometry | 1 | 2007 | 1345 | 0.050 |
Why?
|
| Life Style | 1 | 2013 | 3931 | 0.050 |
Why?
|
| Pain Perception | 1 | 2023 | 198 | 0.050 |
Why?
|
| Probability | 1 | 2007 | 2483 | 0.050 |
Why?
|
| Testosterone | 1 | 2012 | 2493 | 0.050 |
Why?
|
| Androgens | 1 | 2008 | 1285 | 0.050 |
Why?
|
| Incidence | 2 | 2024 | 21547 | 0.040 |
Why?
|
| Postoperative Complications | 3 | 2019 | 15889 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2010 | 4199 | 0.040 |
Why?
|
| Long QT Syndrome | 1 | 2004 | 472 | 0.040 |
Why?
|
| Vitamin D | 1 | 2013 | 3311 | 0.040 |
Why?
|
| Inflammation | 2 | 2024 | 10868 | 0.040 |
Why?
|
| Bisexuality | 1 | 2021 | 295 | 0.040 |
Why?
|
| Fertility | 1 | 2024 | 771 | 0.040 |
Why?
|
| Male | 10 | 2023 | 365203 | 0.040 |
Why?
|
| Endometrium | 1 | 2021 | 406 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4879 | 0.040 |
Why?
|
| Abdomen | 1 | 2023 | 1137 | 0.040 |
Why?
|
| Epithelium | 1 | 2021 | 1607 | 0.030 |
Why?
|
| Middle Aged | 5 | 2021 | 223737 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 20245 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2020 | 518 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 40261 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2004 | 1568 | 0.030 |
Why?
|
| Calcium | 1 | 2009 | 5792 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2020 | 704 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2009 | 8748 | 0.030 |
Why?
|
| Pregnancy | 3 | 2024 | 30265 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 1216 | 0.030 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2004 | 1335 | 0.030 |
Why?
|
| Aging | 1 | 2013 | 8745 | 0.030 |
Why?
|
| Granuloma, Pyogenic | 1 | 2014 | 47 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 565 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 20776 | 0.030 |
Why?
|
| Prognosis | 1 | 2013 | 30046 | 0.030 |
Why?
|
| Counseling | 1 | 2020 | 1554 | 0.030 |
Why?
|
| Liver | 1 | 2008 | 7578 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2018 | 1129 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2018 | 2089 | 0.020 |
Why?
|
| Feeding Behavior | 2 | 2014 | 3205 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2012 | 554 | 0.020 |
Why?
|
| Biopsy | 1 | 2021 | 6805 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 2012 | 396 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2021 | 42683 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3773 | 0.020 |
Why?
|
| Hemangioma | 1 | 2014 | 727 | 0.020 |
Why?
|
| Spironolactone | 1 | 2012 | 415 | 0.020 |
Why?
|
| Patient Selection | 1 | 2020 | 4265 | 0.020 |
Why?
|
| Hormones | 1 | 2012 | 870 | 0.020 |
Why?
|
| Recurrence | 1 | 2020 | 8513 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2012 | 356 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2004 | 4712 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2020 | 3443 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 2360 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 171786 | 0.020 |
Why?
|
| Health Surveys | 1 | 2014 | 4055 | 0.010 |
Why?
|
| Linear Models | 1 | 2014 | 5891 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3438 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 12801 | 0.010 |
Why?
|
| Data Collection | 1 | 2012 | 3324 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 18068 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3628 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 11116 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 26428 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 15471 | 0.010 |
Why?
|